Cargando…

A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats

A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hongjun, Han, Yaotian, Zhang, Yuzhong, Yan, Wenqiang, Xu, Bing, Chu, Fuhao, Xie, Tianxin, Jia, Menglu, Yan, Mengmeng, Zhao, Rui, Wang, Penglong, Lei, Haimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372569/
https://www.ncbi.nlm.nih.gov/pubmed/28272302
http://dx.doi.org/10.3390/ijms18030553
_version_ 1782518645617852416
author Xiang, Hongjun
Han, Yaotian
Zhang, Yuzhong
Yan, Wenqiang
Xu, Bing
Chu, Fuhao
Xie, Tianxin
Jia, Menglu
Yan, Mengmeng
Zhao, Rui
Wang, Penglong
Lei, Haimin
author_facet Xiang, Hongjun
Han, Yaotian
Zhang, Yuzhong
Yan, Wenqiang
Xu, Bing
Chu, Fuhao
Xie, Tianxin
Jia, Menglu
Yan, Mengmeng
Zhao, Rui
Wang, Penglong
Lei, Haimin
author_sort Xiang, Hongjun
collection PubMed
description A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhibition of the rebound of the viral replication rate. Furthermore, Oxy-Di-OA showed good performance of anti-HBV activity in vivo. Some studies showed that liver fibrosis may affiliate with HBV gene mutations. In addition, the anti-hepatic fibrosis activity of Oxy-Di-OA has not been studied. Therefore, we evaluated the protective effect of Oxy-Di-OA against carbon tetrachloride (CCl(4))-induced liver injury in rats. Daily intraperitoneally administration of Oxy-Di-OA prevented the development of CCl(4)-induced liver fibrosis, which was evidenced by histological study and immunohistochemical analysis. The entire experimental protocol lasted nine weeks. Oxy-Di-OA significantly suppressed the increases of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (p < 0.05). Furthermore, Oxy-Di-OA could prevent expression of transforming growth factor β1 (TGF-β1). It is worth noting that the high-dose group Oxy-Di-OA is superior to bifendate in elevating hepatic function. Compared to the model group, Oxy-Di-OA in the high-dose group and low-dose group can significantly reduce the liver and spleen indices (p < 0.05). The acute toxicity test showed that LD(50) and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73–798.73 mg/kg via intraperitoneal injection in mice, respectively. The LD(50) value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice. In addition, a simple and rapid high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated to study the pharmacokinetic characteristics of the compound. After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (C(max) = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.
format Online
Article
Text
id pubmed-5372569
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53725692017-04-10 A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats Xiang, Hongjun Han, Yaotian Zhang, Yuzhong Yan, Wenqiang Xu, Bing Chu, Fuhao Xie, Tianxin Jia, Menglu Yan, Mengmeng Zhao, Rui Wang, Penglong Lei, Haimin Int J Mol Sci Article A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhibition of the rebound of the viral replication rate. Furthermore, Oxy-Di-OA showed good performance of anti-HBV activity in vivo. Some studies showed that liver fibrosis may affiliate with HBV gene mutations. In addition, the anti-hepatic fibrosis activity of Oxy-Di-OA has not been studied. Therefore, we evaluated the protective effect of Oxy-Di-OA against carbon tetrachloride (CCl(4))-induced liver injury in rats. Daily intraperitoneally administration of Oxy-Di-OA prevented the development of CCl(4)-induced liver fibrosis, which was evidenced by histological study and immunohistochemical analysis. The entire experimental protocol lasted nine weeks. Oxy-Di-OA significantly suppressed the increases of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (p < 0.05). Furthermore, Oxy-Di-OA could prevent expression of transforming growth factor β1 (TGF-β1). It is worth noting that the high-dose group Oxy-Di-OA is superior to bifendate in elevating hepatic function. Compared to the model group, Oxy-Di-OA in the high-dose group and low-dose group can significantly reduce the liver and spleen indices (p < 0.05). The acute toxicity test showed that LD(50) and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73–798.73 mg/kg via intraperitoneal injection in mice, respectively. The LD(50) value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice. In addition, a simple and rapid high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated to study the pharmacokinetic characteristics of the compound. After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (C(max) = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively. MDPI 2017-03-06 /pmc/articles/PMC5372569/ /pubmed/28272302 http://dx.doi.org/10.3390/ijms18030553 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xiang, Hongjun
Han, Yaotian
Zhang, Yuzhong
Yan, Wenqiang
Xu, Bing
Chu, Fuhao
Xie, Tianxin
Jia, Menglu
Yan, Mengmeng
Zhao, Rui
Wang, Penglong
Lei, Haimin
A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title_full A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title_fullStr A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title_full_unstemmed A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title_short A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
title_sort new oleanolic acid derivative against ccl(4)-induced hepatic fibrosis in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372569/
https://www.ncbi.nlm.nih.gov/pubmed/28272302
http://dx.doi.org/10.3390/ijms18030553
work_keys_str_mv AT xianghongjun anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT hanyaotian anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT zhangyuzhong anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT yanwenqiang anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT xubing anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT chufuhao anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT xietianxin anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT jiamenglu anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT yanmengmeng anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT zhaorui anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT wangpenglong anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT leihaimin anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT xianghongjun newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT hanyaotian newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT zhangyuzhong newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT yanwenqiang newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT xubing newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT chufuhao newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT xietianxin newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT jiamenglu newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT yanmengmeng newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT zhaorui newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT wangpenglong newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats
AT leihaimin newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats